A by-product of glutathione production in cancer cells may cause disruption in bone metabolic processesThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.

Cancer cell lines release glutamate into the extracellular environment

(2009) Eric P. Seidlitz et al.   CLINICAL & EXPERIMENTAL METASTASIS

The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance

(2008) M Lo et al.   BRITISH JOURNAL OF CANCER

Challenges in cancer pain management–bone pain

(2008) L. Colvin et al.   EUROPEAN JOURNAL OF CANCER

Regulation of the maturation of osteoblasts and osteoclastogenesis by glutamate

(2008) Tzu-Hung Lin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The xc− cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases

(2008) Maisie Lo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Pharmacological Topics of Bone Metabolism: Glutamate as a Signal Mediator in Bone

(2008) Takeshi Takarada et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Small interfering RNA–mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema

(2008) Nicolai E Savaskan et al.   NATURE MEDICINE

Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway

(2008) R-S Chen et al.   ONCOGENE